$9.600
-0.108 (-1.13%)Zum Schluss
- High
- 9.722
- Open
- 9.670
- VWAP
- 9.60
- Vol
- 860.96K
- Mkt Cap
- 122.08M
- Low
- 9.480
- Amount
- 8.27M
- EV/EBITDA, TTM
- 241.48
OptiNose, Inc. is a specialty pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists. The Company's product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing its Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). XHANCE combines the EDS with a liquid formulation of fluticasone propionate, a well-characterized, second-generation corticosteroid. XHANCE is designed to deliver medication into the high and deep regions of the nasal passages where both nasal polyps and inflamed and swollen membranes can obstruct normal sinus ventilation and drainage. It has developed both a liquid delivery EDS and a powder delivery EDS utilizing natural functional behaviors of the upper nasal airways intended to offer better drug deposition.
Analyst Ratings (4)
HC Wainwright & Co.
$9
2025-03-21
HC Wainwright & Co.
2025-03-21
Kursziel
$9
Piper Sandler
$9
2025-03-21
Piper Sandler
2025-03-21
Kursziel
$9
Lake Street
$9
2025-03-20
Lake Street
2025-03-20
Kursziel
$9
Lake Street
$17
2025-01-16
Lake Street
2025-01-16
Kursziel
$17
HC Wainwright & Co.
$18
2025-01-03
HC Wainwright & Co.
2025-01-03
Kursziel
$18
Bewertungskennzahlen
Event-Zeitleiste
News
8.503-16renaissancecapitalOption Therapeutics Lowers IPO Size to $20 Million
8.501-31renaissancecapitalFour IPOs and Ten SPACs Priced This Week
- 8.501-26renaissancecapital
Option Therapeutics Files for $25 Million IPO to Advance Liver Disease Treatments
8.505-21NewsfilterParatek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies
4.005-19BenzingaHC Wainwright & Co. Reiterates Neutral on OptiNose, Maintains $9 Price Target
OPTN FAQ — answered by Alphio AI
OptiNose, Inc. is a specialty pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists. The Company's product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing its Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). XHANCE combines the EDS with a liquid formulation of fluticasone propionate, a well-characterized, second-generation corticosteroid. XHANCE is designed to deliver medication into the high and deep regions of the nasal passages where both nasal polyps and inflamed and swollen membranes can obstruct normal sinus ventilation and drainage. It has developed both a liquid delivery EDS and a powder delivery EDS utilizing natural functional behaviors of the upper nasal airways intended to offer better drug deposition. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
4 analysts cover OPTN: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 9.00.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.